Last reviewed · How we verify
recombinant human alpha B-crystallin — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
recombinant human alpha B-crystallin (recombinant human alpha B-crystallin) — Delta Crystallon BV.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| recombinant human alpha B-crystallin TARGET | recombinant human alpha B-crystallin | Delta Crystallon BV | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- recombinant human alpha B-crystallin CI watch — RSS
- recombinant human alpha B-crystallin CI watch — Atom
- recombinant human alpha B-crystallin CI watch — JSON
- recombinant human alpha B-crystallin alone — RSS
Cite this brief
Drug Landscape (2026). recombinant human alpha B-crystallin — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-alpha-b-crystallin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing